Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TCR alpha/beta+/CD19+ depleted hematopoietic cells |
Trade Name | |
Synonyms | TCR alpha/beta+/CD19+ depleted HPCs||TCR alpha/beta/CD19-depleted HPCs |
Drug Descriptions |
TCR alpha/beta+/CD19+ depleted hematopoietic cells is a preparation of donor hematopoietic progenitor cells that have been treated to remove the CD19 and TCRalpha/beta-expressing populations, potentially resulting in decreased graft vs. host disease after transplantation (PMID: 27811849, PMID: 29431621). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C157370 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
TCR alpha/beta+/CD19+ depleted hematopoietic cells | TCR alpha/beta+/CD19+ depleted hematopoietic cells | 0 | 1 |